Skip to content
Bored Studies
RecruitingPhase 3

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Eli Lilly and Company · NCT07222332

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 1–35 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
300
US sites recruiting
4
Study start
February 5, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

Being studied: Baricitinib; Placebo

Conditions: Diabetes Mellitus, Type 1

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention
  • Have at least one diabetes-related autoantibody found at screening
  • Show signs of remaining beta-cell function
  • stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening
  • Weigh at least 8 kilograms (kg) (18 pounds) at screening

Exclusion Criteria

  • Have any other type of diabetes including gestational
  • Have uncontrolled high blood pressure
  • Have had a heart attack, heart disease, stroke, or heart failure
  • Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
  • Have a current or recent clinically serious medical condition or infection

Recruiting US locations

  • Barbara Davis Center for Childhood Diabetes

    Aurora, CO 80045

    Site contact: 303-724-3861

  • Tallahassee Memorial HealthCare

    Tallahassee, FL 32308

    Site contact: 850-431-5404

  • Driscoll Children's Hospital

    Corpus Christi, TX 78411

    Site contact: 361-739-7250

  • University of Virginia

    Charlottesville, VA 22903

    Site contact: 434-422-2653

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All diabetes studies in Colorado →
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function… (NCT07222332) | Bored Studies